Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma (VOR) amended the employment agreement of Chief Development Officer Dr. Qing Zuraw, effective November 2, 2025, for a five‑month period. If she is terminated without cause, she will receive a lump-sum, pro‑rated portion of her 2025 target bonus and, if applicable, a pro‑rated portion of her 2026 target bonus. If she resigns for any reason after December 31, 2025, she will receive the same severance benefits as a without‑cause termination.
The company also announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer via a November 3, 2025 press release furnished under Regulation FD.
Vor Biopharma (VOR): RA Capital-affiliated reporting persons, identified as a director and 10% owner, reported open-market sales of common stock on October 28–30, 2025.
Disclosed transactions: 87,828 shares at a weighted average price of $27.10; 36,483 shares at $28.18; 251,518 shares at $25.22; and 24,579 shares at $25.12. After these trades, 779,652 shares were beneficially owned indirectly. Prices reflect weighted averages across multiple trades within stated ranges. The shares are held directly by RA Capital Healthcare Fund, L.P., with beneficial ownership disclaimed except to the extent of pecuniary interest.
Vor Biopharma furnished a Regulation FD update via an 8-K. On October 28, 2025, the company hosted a webcast to discuss late‑breaking 48‑week Phase 3 clinical trial data from China for telitacicept in primary Sjögren’s disease. The presentation used in the webcast was furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
Vor Biopharma (VOR): Insider share sales reported by 10% owner/director affiliates. Entities associated with RA Capital reported open-market sales of common stock on three dates. On 10/23/2025, 76,880 shares were sold at $28.01 (weighted average). On 10/24/2025, 53,345 shares were sold at $28.01 (weighted average). On 10/27/2025, 90,941 shares were sold at $28.12 (weighted average).
After these transactions, 1,180,060 shares were beneficially owned indirectly. The filing identifies the reporting persons as RA Capital Management, L.P., RA Capital Management GP, LLC, RA Capital Healthcare Fund, L.P., and individuals including Dr. Peter Kolchinsky and Mr. Rajeev Shah, with holdings held directly by the Fund. Footnotes note weighted-average pricing across ranges and that certain parties disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) insiders affiliated with RA Capital reported open‑market sales of common stock on 10/20/2025 and 10/21/2025. Transactions included 70,366 shares at a weighted average price of $29.63 (range $29.045–$30.025), 6,553 shares at $30.12 (range $30.05–$30.26), and 25,027 shares at $28.11 (range $28.00–$28.475) held indirectly by the RA Capital Healthcare Fund. The RA Capital Nexus Fund sold 13,817 shares at $29.63 and 1,287 shares at $30.12.
Following these transactions, the Healthcare Fund beneficially owned 1,401,226 shares indirectly; the Nexus Fund held 0 shares. The filing was made by more than one reporting person. Reporting persons are noted as Director and 10% Owner and disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.
Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.
Vor Biopharma (VOR): Form 4 insider sales reported. A reporting group including Reprogrammed Interchange LLC sold a total of 73,676 shares of Vor Biopharma common stock on 10/15/2025 and 10/16/2025. The transactions were executed at weighted average prices of $31.0496, $32.0459, $32.7733, and $30.4548.
Following these sales, 1,204,442 shares were beneficially owned as reported after the final transaction. The securities are held by Reprogrammed Interchange LLC; per the disclosure, Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest, and he disclaims beneficial ownership except to the extent of his pecuniary interest. Each sale was executed in multiple trades within disclosed price ranges.
Vor Biopharma (VOR) disclosed insider sales by affiliates of RA Capital on multiple dates. The filing lists open-market sales (Code S) on 10/15/2025, 10/16/2025, and 10/17/2025 at weighted average prices within disclosed ranges. Examples include sales at $30.55 and $31.17 on 10/15, at $29.32 and $30.36 on 10/16, and at $29.12, $30.28, and $31.00 on 10/17.
Following the reported transactions, the table shows beneficially owned amounts of 1,503,172 shares for the Fund and 15,104 shares for the Nexus Fund, each reported as indirectly held. The report notes the issuer’s 1-for-20 reverse stock split on September 18, 2025, and that the reporting persons are identified as a Director and 10% Owner.
Vor Biopharma (VOR) insider filing reports open‑market sales by an affiliate of director Reid Hoffman totaling 96,657 shares across 10/10–10/14/2025, executed at weighted average prices disclosed in the filing. Following these transactions, 1,278,118 shares were beneficially owned.
The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest. The filing was made by more than one reporting person.
Amendment No. 6 to Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman jointly beneficially own 1,374,775 shares of Vor Biopharma Inc., representing 20.1% of the common stock. The filing discloses open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through October 9, 2025, including two recent sales of 75,262 shares on October 8, 2025 at a weighted average price of $33.8651 and 48,884 shares on October 9, 2025 at $32.068. A sequence of prior sales is listed with dates, share amounts and weighted average prices; all share figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. No new agreements, litigation disclosures or changes to voting/dispositive power beyond the reported sales are stated.